Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
Publication
, Conference
Eads, JR; Catalano, PJ; Fisher, GA; Rubin, D; Iagaru, A; Klimstra, DS; Konda, B; Kwong, MS; Chan, JA; De Jesus-Acosta, A; Halfdanarson, TR ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Eads, J. R., Catalano, P. J., Fisher, G. A., Rubin, D., Iagaru, A., Klimstra, D. S., … O’Dwyer, P. J. (2022). Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Eads, Jennifer Rachel, Paul J. Catalano, George A. Fisher, Daniel Rubin, Andrei Iagaru, David S. Klimstra, Bhavana Konda, et al. “Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Eads JR, Catalano PJ, Fisher GA, Rubin D, Iagaru A, Klimstra DS, et al. Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Eads, Jennifer Rachel, et al. “Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Eads JR, Catalano PJ, Fisher GA, Rubin D, Iagaru A, Klimstra DS, Konda B, Kwong MS, Chan JA, De Jesus-Acosta A, Halfdanarson TR, Shaib WL, Soares HP, Hong SC, Wong TZ, O’Dwyer PJ. Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences